Fig. 3: Collateral drug sensitivities can be targeted to limit the growth of drug-resistant variants of M. tuberculosis. | Nature Communications

Fig. 3: Collateral drug sensitivities can be targeted to limit the growth of drug-resistant variants of M. tuberculosis.

From: The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis

Fig. 3

a–d Dose–response curves for selected drug-resistant variants and the drug-susceptible parent against selected antibiotics. Strain names and candidate mutations are listed below each dose-response. Dose-response curves are the results of a single biological replicate from a representative experiment (n > 4 independent experiments). The Gompertz model was used to fit growth data. e–h Time kill assays of selected drug-resistant variants and drug-susceptible variants against sub-inhibitory concentrations (i.e. 0.3× MIC of drug-susceptible parent strain). OD600 data is the mean ± range of biological duplicates from a representative experiment (n > 2 independent experiments). Assays were started at an OD600 of 0.005, and OD600 was determined on stated days. DMSO solvent control graphs are included in Supplementary Fig. 5.

Back to article page